Olcegepant

Olcegepant
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • N-[(1R)-2-[[(1S)-5-Amino-1-[[4-(pyridin-4-yl)piperazin-1-yl]carbonyl]pentyl]amino]-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl]-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H47Br2N9O5
Molar mass869.660 g·mol−1
3D model (JSmol)
SMILES
  • C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6
InChI
  • InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1
  • Key:ITIXDWVDFFXNEG-JHOUSYSJSA-N

Olcegepant (INN,[1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines.[2]

A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo.[3]

See also

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 48" (PDF). World Health Organization. pp. 256–7. Retrieved 20 March 2017.
  2. ↑ Tfelt-Hansen P, Olesen J (April 2011). "Possible site of action of CGRP antagonists in migraine". Cephalalgia. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046. S2CID 22049557.
  3. ↑ Yao G, Yu T, Han X, Mao X, Li B (April 2013). "Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis". Neural Regeneration Research. 8 (10): 938–47. doi:10.3969/j.issn.1673-5374.2013.10.009. PMC 4145922. PMID 25206386.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.